To report preliminary results of a new closed-skin, transcutaneous bone conduction device (BCD) in 6 children with high-grade ear atresia
Tertiary care center; prospective study; we evaluated the gain with masking of the contralateral ear and the benefit of hearing rehabilitation with the transcutaneous BCD in noise: speech-in-noise tests, conducted in real life condition (with contralateral ear unmasked and fitted with a hearing device if done before implantation), with and without BCD, with determination of the speech reception threshold (SRT). Children and parent’s satisfaction was assessed.
Patients’ ages ranged from 6 to 9 years. All had high-grade ear atresia with a preoperative mean pure-tone average (PTA) loss of 71.46 ± 6.59 dB on air conduction and 14 ± 4.98 dB on bone conduction. At M6, all children used the implant 5 to 12 hours daily (mean, 10) without pain or cutaneous complications. At M6, the mean air conduction PTA with transcutaneous BCD was 28.45 ± 1.68 dB, the mean gain 43 ± 6.96 dB, and the mean SRT gain 33.33 ± 10.75 dB. Using speech-in-noise tests in real-life conditions, the mean SRT was statistically improved with the transcutaneous BCD (−8 ± 2.83 dB, p = 0.0313). Both children and parents reported being satisfied or very satisfied.
These preliminary results show satisfactory functional gain, cutaneous tolerance, and patients’ satisfaction with the new transcutaneous BCD.